Amgen Q2 2026: revenue up 10%, GAAP EPS up 65%, adjusted EPS up 4%
FROM THE WIRE · FINANCE.YAHOO.COM
Amgen Inc. (NASDAQ:AMGN) has carved out a strong spot in the biotech world, thanks to its lineup of medicines for cancer, heart disease, inflammation, and some rare conditions. The company's tried-and-true products bring in plenty of cash, and its newer treatments show real…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: neutralResults show strong margin gains, but slower adjusted EPS growth keeps the growth question open for the stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Amgen's Q2 2026 revenue rose 10% year on year to $10.1 billion.
- 02GAAP EPS jumped 65% to $4.37, while adjusted EPS grew 4% to $6.29.
- 03The operating margin improved to 36.8% from 30.3%.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets